UNASSIGNED: We evaluated the @entity158 and radiologic response, time to progression, and dose-response relationship after palliative radiotherapy for bone metastasis from @entity157 . We retrospectively reviewed the medical records of 91 @entity1 between January 2004 and August 2012. The reviewed medical records included data on changes in @entity158 progression, and radiologic response evaluated via follow-up images. The radiologic response was assessed based on the Response Evaluation Criteria In @entity5 . The @entity158 response was defined according to the International Bone Metastases Consensus Working Party palliative radiotherapy endpoints. Median radiation dose was 40 Gy (range, 20-66 Gy), with various fraction sizes (range, 2.0-6.0 Gy). @entity158 response rate was 81.4%. During the follow-up periods, radiologic local @entity5 progression was found in 42 @entity1 (46.2%). The median time to progression was 14.1 months. When the @entity1 were divided into two groups according to their radiation dose (< 55 Gy10 vs. >=  55 Gy10), the @entity158 response rates of the high- and low-dose groups did not differ significantly (p = 0.728). However, the radiologic response rate and the time to progression showed significant differences between the two groups (p = 0.009 and p = 0.018, respectively). With dose escalation, higher radiologic response rates and a longer time to progression were achieved in @entity1 with mass-forming bone metastases from @entity157 .

High-dose radiotherapy is associated with better local control of bone metastasis from XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity157 :: ('MESH:D006528', 'Disease') :: ['hepatocellular carcinoma'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Solid Tumors'] @entity158 :: ('MESH:D010146', 'Disease') :: ['Pain', 'pain', 'pain, local tumor']
@entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']
